RedHill Biopharma Ltd 6-K, filed Oct 13, 2026
RedHill Biopharma Ltd. (RDHL)
About this 6-K
RedHill Biopharma Ltd filed this 6-K on October 13, 2026.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of October 2026
Commission File No.:001-35773
REDHILL BIOPHARMA LTD.
(Translation of registrant’s name into English)
21 Ha’arba’a Street, Tel Aviv, 6473921, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On October 13, 2026, RedHill Biopharma Ltd. (the “Company”) filed a prospectus supplement to increase the maximum aggregate
offering amount of the American Depositary Shares, each representing ten thousand (10,000) of its ordinary shares, no par value, that
may be issued and sold from time to time under the At The Market Offering Agreement that the Company entered into with H.C. Wainwright
& Co., LLC on February 3, 2025.
Attached hereto and incorporated by reference in this Report on Form 6-K are the following exhibits:
Exhibit 5.1: Goldfarb Gross Seligman & Co..
Exhibit 5.2: Opinion of Haynes and Boone, LLP.
Exhibit 23.1: Consent of Goldfarb Gross Seligman & Co. (included in Exhibit 5.1).
Exhibit 23.2: Consent of Haynes and Boone, LLP (included in Exhibit 5.2).
This Form 6-K is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122), on July 24, 2019 (File No. 333-232776), on March 25, 2021 (File No. 333-254692), on May 3, 2021 (File No. 333-255710), on January 11, 2022 (File No. 333-262099), on June 27, 2022 (File No. 333-265845), on June 29, 2023 (File No. 333-273001), on June 20, 2024 (File No. 333-280327), on March 25, 2025 (File No. 333-286082) and on January 22, 2026 (File No. 333-292879), and its Registration Statements on Form F-3 filed with the Securities and Exchange Commission on March 30, 2021 (File No. 333-254848), on August 4, 2023 (File No. 333-273709), on October 13, 2023 (File No. 333-274957), as amended, on August 9, 2024 (File No. 333-281417) and on July 2, 2026 (333-297223).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| REDHILL BIOPHARMA LTD. | |||
| (the “Registrant”) | |||
| Date: October 13, 2026 | By: | /s/ Dror Ben-Asher | |
| Name: | Dror Ben-Asher | ||
| Title: | Chief Executive Officer | ||
Exhibit 5.1
Tel Aviv, October 13, 2026
RedHill Biopharma Ltd.
21 Ha’arba’a Street
Tel Aviv, 6473921
Israel - Final
Re: RedHill Biopharma Ltd.
Ladies and Gentlemen:
We have acted as Israeli counsel for RedHill Biopharma Ltd., a company organized under the laws of Israel (the “Company”), in connection with the sale by the Company through the Agent (as defined below) of American Depositary Shares (“Placement ADSs”), each representing ten thousand (10,000) ordinary shares, no par value (the “Underlying Shares”), of the Company, having an aggregate offering price of up to $2,587,409, from time to time, pursuant to the At The Market Offering Agreement between the Company and H.C. Wainwright & Co., LLC (the “Agent”), dated February 3, 2025 (the “Agreement”).
The Placement ADSs will be issued pursuant to a registration statement on Form F-3 (Registration Statement No. 333-281417) filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), on August 9, 2024, and declared effective by the Commission on August 19, 2024 (including information deemed incorporated by reference therein in accordance with applicable rules of the Commission, the “Registration Statement”), the base prospectus contained therein, dated August 19, 2024, forming part of the Registration Statement, with respect to the offering from time to time of the Company’s securities (the “Base Prospectus”), and the prospectus supplements dated February 3, 2025, November 26, 2025, May 7, 2026, June 29, 2026 and October 13, 2026 relating to the offering from time to time of the Placement ADSs under the Agreement, as filed with the Commission pursuant to Rule 424(b) under the Securities Act (the “Prospectus Supplement”, together with the Base Prospectus and all information incorporated by reference therein, the “Prospectus”).
In connection therewith, we have examined and relied upon copies of the Registration Statement, the Prospectus, the Company’s amended and restated articles of association and such corporate records, certificates, instruments, and other documents relating to the Company and such matters of law as we have deemed necessary or appropriate for the purpose of rendering this opinion. In such examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to the originals of all documents submitted to us as copies, the truth, accuracy and completeness of the information, representations and warranties contained in the corporate records, certificates, instruments and documents we have reviewed, and the legal capacity of all natural persons. As to any facts material to such opinion, we have relied on certificates of public officials and certificates of officers or other representatives of the Company. We have also assumed that (i) prior to the issuance of any of the Underlying Shares under the Agreement, the price, number of Placement ADSs and certain other terms of issuance with respect to any specific Sales Notice (as defined in the Agreement) delivered under the Agreement will be authorized and approved by the Company’s board of directors or a pricing committee of the Company’s board of directors in accordance with Israeli law (the “Corporate Proceedings”) and (ii) upon the issuance of any Underlying Shares, the total number of ordinary shares of the Company issued and outstanding will not exceed the total number of ordinary shares that the Company is then authorized to issue under its amended and restated articles of association.
Based upon the foregoing and in reliance thereon, assuming the completion of the Corporate Proceedings in connection with the delivery of a specific Sales Notice, we are of the opinion that the Underlying Shares to be offered and sold under the Agreement have been duly authorized for issuance and, when issued and paid for in accordance with the terms and conditions of the Agreement, will be validly issued, fully paid and non-assessable.
We are members of the Israeli bar, and we express no opinion as to any matter relating to the laws of any jurisdiction other than the laws of the State of Israel and have not, for the purpose of giving this opinion, made any investigation of the laws of any other jurisdiction than the State of Israel.
We hereby consent to the filing of this opinion as an Exhibit 5.1 to the Company’s Current Report on Form 6-K to be submitted with the Commission on or about June 29, 2025, which will be incorporated by reference in the Registration Statement. In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.
|
Very truly yours,
/s/ Goldfarb Gross Seligman & Co. |
2
Exhibit 5.2
 |
 |
Haynes and Boone, LLP
Attorneys and Counselors
30 Rockefeller Plaza
22nd Floor
New York, New York 10112
T (212) 659-7300
F (212) 918-8989
www.haynesboone.com
October 13, 2026
RedHill Biopharma Ltd.
21 Ha'arba'a Street
Tel Aviv 6473921
Israel
Ladies and Gentlemen:
We have acted as special U.S. counsel to RedHill Biopharma Ltd., a company organized under the laws of the State of Israel (the “Company”), in connection with the sale of the Company’s American Depositary Shares (the “ADSs”), each ADS representing ten thousand (10,000) ordinary shares of the Company, no par value (the “Ordinary Shares”), having an aggregate offering price of up to $2,587,409, pursuant to the registration statement on Form F-3 (the “Registration Statement”) filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), on August 9, 2024, including the base prospectus, dated August 19, 2024, as supplemented by the prospectus supplements, dated February 3, 2025, November 26, 2025, May 7, 2026, June 29, 2026 and October 13, 2026, each forming part of the Registration Statement. This opinion is being rendered in connection with the offering and sale by the Company of the ADSs pursuant to the terms of an At The Market Offering Agreement, dated February 3, 2025, by and between the Company and H.C. Wainwright & Co., LLC. The ADSs will be issued pursuant to a Deposit Agreement, dated as of December 26, 2012, by and among the Company, The Bank of New York Mellon, as depositary, and owners and holders from time to time of ADSs issued thereunder (as amended, the “Deposit Agreement”).
In connection with this opinion, we have examined such corporate records, documents, instruments, certificates of public officials and of the Company, and such questions of law as we have deemed necessary for the purpose of rendering the opinions set forth herein.
In such examination, we have assumed the genuineness of all signatures and the authenticity of all items submitted to us as originals and the conformity with originals of all items submitted to us as copies and the legal competence of all signatories to such documents.
Based on the foregoing, and subject to the further assumptions and qualifications set forth below, it is our opinion that, when the ADSs are issued in accordance with the Deposit Agreement against the deposit of duly authorized, validly issued, fully paid and non-assessable Ordinary Shares, such ADSs will be duly and validly issued under the Deposit Agreement and will entitle the holders thereof to the rights specified therein.
RedHill Biopharma Ltd.
October 13, 2026
Page 2
Please note that we are opining only as to the matters expressly set forth herein, that no opinion should be inferred as to any other matter. We are opining herein as to the laws of the State of New York as in effect on the date hereof, and we express no opinion with respect to any other laws, rules, or regulations. This opinion is based upon currently existing laws, rules, regulations, and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein. In rendering the foregoing opinions, we have relied, for matters involving Israeli law, solely on the opinion of Goldfarb Gross Seligman & Co., Israeli counsel to the Company.
This opinion is being rendered solely in connection with the registration of the offering and the sale of the ADSs, pursuant to the registration requirements of the Securities Act.
We hereby consent to the use of this opinion as Exhibit 5.2 to the Company’s Report on Form 6-K to be filed with the Commission on or about October 13, 2026, which will be incorporated by reference in the Registration Statement, and to the reference to us under the caption “Legal Matters” in the Registration Statement. In giving such consent, we do not hereby admit that we are acting within the category of persons whose consent is required under Section 7 of the Securities Act or the rules or regulations of the Commission thereunder. This opinion is given as of the date hereof and we assume no obligation to update or supplement such opinion to reflect any facts or circumstances that may hereafter come to our attention or any changes that may hereafter occur.
Very truly yours,
/s/ Haynes and Boone, LLP
Haynes and Boone, LLP